27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Data readouts triggered some stock-specific reactions. Phio Pharmaceuticals, Inc. (NASDAQ:PHIO) was among the best performers for the week after reporting positive preclinical data on an RNAi therapeutic candidate meant to enhance the efficacy of anti-PD-1 antibody therapies.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
On the regulatory front, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) received FDA approval for its BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation associated with neuropsychiatric disorders. Novartis AG's (NYSE:NVS) Vijoice was greenlighted as a treatment option for adult and pediatric patients with severe manifestations of PIK3CA-related Overgrowth Spectrum who require systemic therapy.
Pfizer, Inc. (NYSE:PFE) was also in the spotlight following its announcement regarding a $525 million deal to buy respiratory syncytial vaccine company ReViral.
Here are the key catalysts for the unfolding week:
Conferences
American Association for Cancer Research, or AACR, Annual Meeting 2022: April 8-13, in New Orleans, Louisiana
Society for Inherited Metabolic Disorders, or SIMD, Annual Meeting: April 10-13, in Orlando, Florida
Annual Needham Virtual Healthcare Conference: April 11-14
PDUFA Dates:
The FDA is scheduled to rule on Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) biologic license application for REGEN-COV as a prophylactic treatment for COVID-19. The PDUFA goal date is Wednesday, April 13.
Related Link: Merck Continues to See Executive Exodus; Here's A Look At All Recent Departures
Clinical Readouts/Presentations
AACR Meeting Presentations
Vaccinex, Inc. (NASDAQ:VCNX): data from the Phase 1/2 study of pepinemab, in combination with Merck, Inc.'s (NYSE:MRK) Keytruda as first-line treatment of recurrent or metastatic head and neck cancer (Monday)
IN8bio, Inc. (NASDAQ:INAB): Phase 1 data for temozolomide in primary high-grade gliomas (Monday)
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Bicycle Therapeutics plc (NASDAQ:BCYC): interim Phase I results from the Phase 1/2 trial of BT8009 in solid tumors (Monday)
Repare Therapeutics Inc. (NASDAQ:RPTX): clinical data from the Phase 1/2 trial of RP-3500 in solid tumors (Monday)
Eli Lilly and Company ((NYSE: LLY): data from Phase 1b study of pirtobrutinib, in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia (Monday)
Kintara Therapeutics, Inc. (NASDAQ:KTRA): Phase 2 data for dianhydrogalactitol (VAL-083) for the treatment of glioblastoma multiforme (Monday)
Celsion Corporation (NASDAQ:CLSN): data from the Phase 1b dose-escalating study of GEN-1 in the neoadjuvant treatment of patients with Stage III/IV ovarian cancer (Monday)
C4 Therapeutics, Inc. (NASDAQ:CCCC): data from the Phase 1/2 study of CFT7455 in multiple myeloma (Tuesday)
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI): biomarker signature data from the Phase 1b study of vidutolimod in combination with Keytruda in melanoma (Tuesday)
Gracell Biotechnologies Inc. (NASDAQ:GRCL): early results of a safety and efficacy study of allogeneic TruUCAR GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (Tuesday)
Alpine Immune Sciences, Inc. (NASDAQ:ALPN): results from the dose escalation portion of a Phase 1 clinical trial of davoceticept (ALPN-202) as monotherapy in advanced malignancies (Tuesday)
HOOKIPA Pharma Inc. (NASDAQ:HOOK): Phase 1/2 data for HB-201 and HB-202 for the treatment-refractory HPV16+ cancers (Tuesday)
Kura Oncology, Inc. (NASDAQ:KURA): data from the Phase 1/2 trial of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (Wednesday)
SIMD Meeting Presentations
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE): additional data from the PEACE Phase 3 study of pegzilarginase for the treatment of patients with Arginase 1 Deficiency (Monday, 10-11 pm ET)
Travere Therapeutics, Inc. (NASDAQ:TVTX): initial results from the Phase 1/2 study of pegtibatinase, an investigational enzyme replacement therapy, for the treatment of classical homocystinuria (Monday, 8-10 pm ET)
Earnings
Theratechnologies Inc. (NASDAQ:THTX) (Wednesday, before the market open)
BeyondSpring, Inc. (NASDAQ:BYSI) (Thursday, before the market open)
Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.